Gilead COVID Drug Remdesivir Should Consider Trial Failure B
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
Health officials reviewing Gilead Science Inc’s remdesivir against COVID-19 should consider all evidence, including a trial in which the medicine failed, before giving it the green light, the top WHO scientist said on 23 October.

U.S. regulators appeared not to have done so when approving the drug this week, Soumya Swaminathan told a news conference.

Last week, the U.S. Food and Drug Administration approved Gilead’s antiviral drug for treating patients hospitalized with COVID-19, making it the first and only drug approved for the disease in the United States.

FDA decision came a week after the release of the results of the World Health Organization’s Solidarity trial, which concluded remdesivir has little or no impact on a patient’s chances of surviving COVID-19.

“The Solidarity results do not refute these findings of benefit to patients,” the FDA said in a statement posted on its website.

“We have apprised FDA of the topline WHO Solidarity trial results and the draft manuscript” submitted to a publication, the company said. “However, at this time Gilead has not received the requested datasets from WHO for the Solidarity trial results.”

Source: https://in.reuters.com/article/health-coronavirus-remdesivir-who/who-nations-mulling-gileads-covid-drug-should-consider-trial-flop-too-idINKBN279055
M●●●●●●●u M●●●●●●a R●o and 4 others like this1 share
Like
Comment
Share